YiChang HEC ChangJiang Pharmaceutical Dirección
Dirección controles de criterios 3/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Juncai Jiang
Chief Executive Officer (CEO)
CN¥2.6m
Compensación total
| Porcentaje del salario del CEO | 18.7% |
| Permanencia del CEO | 9yrs |
| Participación del CEO | 0.008% |
| Permanencia media de la dirección | 6.8yrs |
| Promedio de permanencia en la Junta Directiva | 6.8yrs |
Actualizaciones recientes de la dirección
Recent updates
Do YiChang HEC ChangJiang Pharmaceutical's (HKG:1558) Earnings Warrant Your Attention?
Apr 23
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) P/S Is Still On The Mark Following 33% Share Price Bounce
Mar 01Investors Appear Satisfied With YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Prospects As Shares Rocket 33%
Mar 01YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Business Is Trailing The Industry But Its Shares Aren't
Jan 03YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Could Easily Take On More Debt
Sep 25Does YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Have A Healthy Balance Sheet?
Nov 25Is YiChang HEC ChangJiang Pharmaceutical (HKG:1558) A Risky Investment?
Mar 23Does This Valuation Of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Imply Investors Are Overpaying?
Oct 29Here's Why YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Has A Meaningful Debt Burden
Apr 13YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Analysts Just Cut Their EPS Forecasts Substantially
Mar 23YiChang HEC ChangJiang Pharmaceutical's(HKG:1558) Share Price Is Down 55% Over The Past Three Years.
Mar 13YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Is Growing Earnings But Are They A Good Guide?
Feb 20
Do Institutions Own YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Shares?
Feb 02YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Dec 26Key Things To Watch Out For If You Are After YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) 5.1% Dividend
Dec 13What Type Of Returns Would YiChang HEC ChangJiang Pharmaceutical's(HKG:1558) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Nov 30Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | CN¥3m | CN¥482k | CN¥2b |
| Sep 30 2023 | n/a | n/a | CN¥2b |
| Jun 30 2023 | n/a | n/a | CN¥1b |
| Mar 31 2023 | n/a | n/a | CN¥608m |
| Dec 31 2022 | CN¥1m | CN¥600k | CN¥77m |
| Sep 30 2022 | n/a | n/a | -CN¥18m |
| Jun 30 2022 | n/a | n/a | -CN¥113m |
| Mar 31 2022 | n/a | n/a | -CN¥351m |
| Dec 31 2021 | CN¥1m | CN¥490k | -CN¥588m |
| Sep 30 2021 | n/a | n/a | -CN¥436m |
| Jun 30 2021 | n/a | n/a | -CN¥285m |
| Mar 31 2021 | n/a | n/a | CN¥277m |
| Dec 31 2020 | CN¥756k | CN¥229k | CN¥839m |
| Sep 30 2020 | n/a | n/a | CN¥1b |
| Jun 30 2020 | n/a | n/a | CN¥2b |
| Mar 31 2020 | n/a | n/a | CN¥2b |
| Dec 31 2019 | CN¥393k | CN¥222k | CN¥2b |
| Sep 30 2019 | n/a | n/a | CN¥2b |
| Jun 30 2019 | n/a | n/a | CN¥1b |
| Mar 31 2019 | n/a | n/a | CN¥1b |
| Dec 31 2018 | CN¥365k | CN¥209k | CN¥943m |
| Sep 30 2018 | n/a | n/a | CN¥961m |
| Jun 30 2018 | n/a | n/a | CN¥980m |
| Mar 31 2018 | n/a | n/a | CN¥813m |
| Dec 31 2017 | CN¥324k | CN¥194k | CN¥647m |
Compensación vs. Mercado: La compensación total de Juncai($USD175.89K) está por debajo de la media de empresas de tamaño similar en el mercado Hong Kong ($USD552.33K).
Compensación vs. Ingresos: La compensación de Juncai ha aumentado más de un 20% en el último año.
CEO
Juncai Jiang (41 yo)
9yrs
Permanencia
CN¥2,572,000
Compensación
Mr. Juncai Jiang has been General Manager and Executive Director of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. since joining in May 2015. Mr. Jiang served as Deputy Head of the traditional Chinese med...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| GM & Executive Director | 9yrs | CN¥2.57m | 0.0076% CN¥ 824.2k | |
| Head of the Sales Department | 10yrs | CN¥645.00k | 0.0076% CN¥ 819.8k | |
| Deputy GM & Executive Director | 9yrs | CN¥2.71m | 0.0076% CN¥ 829.6k | |
| Deputy GM & Executive Director | 9yrs | CN¥1.32m | 0.0076% CN¥ 824.2k | |
| Executive Director | less than a year | CN¥1.59m | sin datos | |
| CFO & Head of Finance Department | 5.3yrs | CN¥480.38k | sin datos | |
| Chief of Quality Division & Employee Representative Supervisor | 6.8yrs | sin datos | 0.0036% CN¥ 395.3k | |
| Joint Company Secretary | 5.6yrs | CN¥370.31k | sin datos | |
| Joint Company Secretary | 2.3yrs | sin datos | sin datos |
6.8yrs
Permanencia media
42yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de 1558 es experimentado (6.8 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| GM & Executive Director | 9yrs | CN¥2.57m | 0.0076% CN¥ 824.2k | |
| Deputy GM & Executive Director | 18.3yrs | CN¥2.71m | 0.0076% CN¥ 829.6k | |
| Deputy GM & Executive Director | 5.9yrs | CN¥1.32m | 0.0076% CN¥ 824.2k | |
| Executive Director | less than a year | CN¥1.59m | sin datos | |
| Chief of Quality Division & Employee Representative Supervisor | 6.8yrs | sin datos | 0.0036% CN¥ 395.3k | |
| Non-Executive Chairman | 9yrs | CN¥32.19m | 0.015% CN¥ 1.6m | |
| Independent Non-Executive Director | 9yrs | CN¥100.00k | sin datos | |
| Supervisor | 6.9yrs | sin datos | 0.0076% CN¥ 824.2k | |
| Chairman of the Board of Supervisors | 4.9yrs | sin datos | sin datos | |
| Independent Non Executive Director | 3.9yrs | CN¥100.00k | sin datos | |
| Independent Non-Executive Director | 3.7yrs | CN¥340.00k | 0.00045% CN¥ 48.9k |
6.8yrs
Permanencia media
45yo
Promedio de edad
Junta con experiencia: La junta directiva de 1558 se considera experimentada (6.8 años de antigüedad promedio).